129 related articles for article (PubMed ID: 24671490)
1. The siRNA-mediated downregulation of N-Ras sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors.
Ahn JH; Lee M
Mol Cell Biochem; 2014 Jul; 392(1-2):239-47. PubMed ID: 24671490
[TBL] [Abstract][Full Text] [Related]
2. Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.
Jang GH; Kim NY; Lee M
Mol Cell Biochem; 2015 Aug; 406(1-2):53-62. PubMed ID: 25912549
[TBL] [Abstract][Full Text] [Related]
3. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
4. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip¹.).
Jang GH; Lee M
Life Sci; 2014 Apr; 102(1):41-8. PubMed ID: 24625733
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF.
Kim JH; Ahn JH; Lee M
Cancer Res Treat; 2017 Oct; 49(4):947-959. PubMed ID: 28052651
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors.
Hwang SH; Ahn JH; Lee M
Genes Genomics; 2019 Nov; 41(11):1273-1280. PubMed ID: 31388978
[TBL] [Abstract][Full Text] [Related]
7. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
8. Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells.
Ahn JH; Han BI; Lee M
Biomol Ther (Seoul); 2015 Jul; 23(4):320-6. PubMed ID: 26157547
[TBL] [Abstract][Full Text] [Related]
9. Increase in the sensitivity to PLX4720 through inhibition of transcription factor EB-dependent autophagy in BRAF inhibitor-resistant cells.
Yeom H; Hwang SH; Kim HG; Lee M
Toxicol Res; 2022 Jan; 38(1):35-44. PubMed ID: 35070939
[TBL] [Abstract][Full Text] [Related]
10. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
11. Autophagy-Dependent Survival of Mutant B-Raf Melanoma Cells Selected for Resistance to Apoptosis Induced by Inhibitors against Oncogenic B-Raf.
Ahn JH; Lee M
Biomol Ther (Seoul); 2013 Mar; 21(2):114-20. PubMed ID: 24009868
[TBL] [Abstract][Full Text] [Related]
12. AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma.
Hu W; Jin L; Jiang CC; Long GV; Scolyer RA; Wu Q; Zhang XD; Mei Y; Wu M
Cell Death Dis; 2013 Nov; 4(11):e914. PubMed ID: 24201813
[TBL] [Abstract][Full Text] [Related]
13. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.
Phadke MS; Sini P; Smalley KS
Mol Cancer Ther; 2015 Jun; 14(6):1354-64. PubMed ID: 25873592
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
[TBL] [Abstract][Full Text] [Related]
15. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Paraiso KH; Xiang Y; Rebecca VW; Abel EV; Chen YA; Munko AC; Wood E; Fedorenko IV; Sondak VK; Anderson AR; Ribas A; Palma MD; Nathanson KL; Koomen JM; Messina JL; Smalley KS
Cancer Res; 2011 Apr; 71(7):2750-60. PubMed ID: 21317224
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic BRAF inhibitor UAI-201 induces cell cycle arrest and autophagy in BRAF mutant glioma cells.
Ahn JH; Lee YW; Ahn SK; Lee M
Life Sci; 2014 May; 104(1-2):38-46. PubMed ID: 24721513
[TBL] [Abstract][Full Text] [Related]
18. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
19. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
20. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
